12th Edition of International Conference on
Neurology and Neurological Disorders
June 22-24, 2026 | Barcelona, Spain
Neuropharmacology and Novel Drug Development
Neuropharmacology and novel drug development are at the forefront of tackling neurological and psychiatric disorders. This field focuses on understanding the interactions between drugs and the nervous system to design targeted therapies. Advances in receptor biology, neurotransmitter dynamics, and signal transduction pathways are driving innovations in drug discovery. Emerging technologies, such as high-throughput screening and in silico modeling, accelerate the identification of potential therapeutic compounds. Breakthroughs in neuropharmacology also emphasize precision medicine, tailoring treatments to individual genetic and biochemical profiles. These developments hold promise for addressing challenges in managing disorders like schizophrenia, epilepsy, and neurodegeneration effectively.
Ken Ware
NeuroPhysics Therapy Institute, Australia
Robert B Slocum
University of Kentucky HealthCare, United States
Yong Xiao Wang
Albany Medical College, United States
Milton Cesar Rodrigues Medeiros
Hospital Santa Casa de Arapongas, Brazil
Zhenhuan Liu
Guangzhou University of Chinese Medicine, China
Jaqueline Tuppen
COGS Club, United Kingdom
Luiz Moutinho
University of Suffolk, United KingdomSubmit your abstract Today
Title : Perception and individuality in patient cases identifying the ongoing evolution of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Ken Ware, NeuroPhysics Therapy Institute, Australia
Title : Narrative medicine: A communication therapy for the communication disorder of Functional Seizures (FS) [also known as Psychogenic Non-Epileptic Seizures (PNES)]
Robert B Slocum, University of Kentucky HealthCare, United States
Title : Personalized and Precision Medicine (PPM), as a unique healthcare model through biodesign-driven biotech and biopharma, translational applications, and neurology-related biomarketing to secure human healthcare and biosafety
Sergey Victorovich Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Neuro sensorium
Luiz Moutinho, University of Suffolk, United Kingdom
Title : GBF1 inhibition reduces amyloid-beta levels in viable human postmortem Alzheimer's disease cortical explant and cortical organoid models
Sean J Miller, Yale School of Medicine, United States
Title : Traumatic Spinal Cord Injuries (tSCI) - Are the radiologically based “advances” in the management of the injured spine evidence-based?
W S El Masri, Keele University, United Kingdom